Global Mumps Vaccine
Market Report
2024
Mumps Vaccine Market Report 2024 (Global Edition)
The Global Mumps Vaccine market size was USD 2.15 Billion in 2022 and it is forecasted to reach USD 3.46 by 2030. Mumps Vaccine Industry's Compound Annual Growth Rate will be 6.12 % from 2023 to 2030.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 3
Share your contact details to receive free updated sample copy/pages of the recently published edition of Mumps Vaccine Market Report 2024.
Global Mumps Vaccine Market Report 2024 Market Size Split by Age Type (Adult, Paediatric), by Distribution channel (Hospital & Clinic, Vaccination Centres)
As per Cognitive Market Research's latest published report, the Global Mumps Vaccine market size was USD 2.15 Billion in 2022 and it is forecasted to reach USD 3.46 Billion by 2030. Mumps Vaccine Industry's Compound Annual Growth Rate will be 6.12 % from 2023 to 2030.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Mumps Vaccine Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 6.12% |
| Market Split by Age Type |
|
| Market Split by Distribution channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Mumps Vaccine industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Mumps Vaccine Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Mumps Vaccine Market Report Description
Introduction of Mumps Vaccine
Mumps viruses are infectious. A fever, headache, muscle aches, feeling worn out and loss of appetite are frequently the first symptoms. The majority of patients then have salivary gland oedema. The sensitive, swelling jaw and puffed-up cheeks are the result of it. The Mumps is often a benign condition. However, it can result in severe, long-lasting issues, such as encephalitis, orchitis in males, oophoritis and mastitis in females. The mumps vaccines are also called MMR vaccines, which protect against measles, mumps, and rubella. Children typically receive the first dose between the ages of 9 and 15 months, followed by the second dose between the ages of 15 and 6 years, with a Minimum of four weeks in between each dose. Increasing research for combination vaccines and increasing infection are prime drivers of the market.
Factors Impacting on Mumps Vaccine Market Growth
- Increasing development of vaccines
Due to a sizable population of health-conscious consumers, the pharmaceutical sector is growing and developing, which offers a chance for the mumps vaccine market to expand. Due to the availability of improving healthcare infrastructure, increasing unmet healthcare needs, growing prevalence of infectious diseases like the mumps diseases and surge in demand for mumps vaccines, the emerging market. In addition, the growth of the mumps vaccine market is being driven by an increase in demand for better healthcare services.
- Increasing government initiatives
Government initiatives to develop vaccines are increasing and funding for research and development is expanding as well, that is supporting market expansion. The MMR virus outbreak globally increased growth placing tremendous burden on the health department. The government launched a vaccine drive, among other initiatives, to combat this infectious disease. Government attempts to raise knowledge of the MMR vaccines and immune population through vaccination campaigns. For instance, the measles and rubella campaign was run by the Indian government that helps in establishment of population immunity in this by ensuring at least 95% coverage.
The Restraining Factor for Mumps Vaccine Market
-
Side effects of vaccination
The market for measles, mumps and rubella vaccines may be constrained in its expansion by adverse reaction to immunisations. For instance, the trivalent combination measles, mumps and rubella vaccination was discounted in Japan in 1989 due to an outbreak of non-viral meningitis and other harmful side effects that would have limited the market for MMR vaccines.
-
High cost of vaccines
Another factor limiting market expansion is the expensive cost of a single dose of the vaccines. Measles, mumps and rubella vaccines cost are high due to special storage and handling requirements, a small number of vaccines available, strict manufacturing and approval standard, demand and supply gaps during disease outbreaks and other factors.
Opportunities on Mumps vaccine market
-
Growing investment pharmaceutical companies
The market is expected to grow due to an increase in significant investment by pharmaceutical companies in R&D efforts. However, growing investment from government and non-government organizations in vaccines boost the growth of the market. Therefore the increasing investment by pharmaceutical companies in developing and underdeveloped countries boost the market growth.
Impact of the COVID-19 pandemic on the Mumps vaccine Market
The covid-19 have a negative impact on the mumps vaccine market. Immunisation is one of the most effective public health measures for the prevention of disease, which has decreased in recent years, according to the World Health Organisation (WHO). Global vaccination rates have decreased as a result of the COVID-19 pandemic and related illnesses, and 25 million children will not have had their vaccinations in 2021. Additionally, COVID-19 has endangered campaigns to raise awareness of viral illnesses including the mumps, measles, and rubella as a result of the healthcare industry focusing its resources and attention on COVID-19. The increase in COVID-19 financing also decreased government immunisation campaigns and funding, which further decreased the number of patients choosing to receive the mumps vaccine.
We have various report editions of Mumps Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Mumps Vaccine Market Insights Video
Mumps Vaccine Industry News
June 2022, GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
August 2021, MMR vaccines for children help to protect front line from covid-19
In order to determine whether the MMR vaccine for children could protect front-line medical personnel from the Covid-19 virus or minimise the severity of the illness for those who get it, researchers from South Africa initiated a clinical experiment. The trials were launched by researchers from the Universities of the Witwatersrand (UW) and Cape Town (UCT) in South Africa.
Top Companies Market Share in Mumps Vaccine Industry: (In no particular order of Rank)
- Sanofi SA
- Pfizer
- AstraZeneca
- Johnson & Johnson
- GlaxoSmithKline
- Novartis
- CSL limited
- VBI Vaccines
- Bharat Biotech
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The North American Mumps Vaccine Market dominates the largest share of the global market
North America dominates the market. The incidence of mumps in North America has increased in the last few years. For example , the world health organization estimates that in 2020 there will be 3522 and 3780 mumps cases in Mexico and the United states, respectively. The incidence of mumps is increasing in the region, which increases the demand for mumps. It has cancer vaccines and supports the global economy. The measles vaccines market is also driven by new launches and product recommendations from key market players in the segment.
The current report Scope analyzes Mumps Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Mumps Vaccine Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Mumps Vaccine Market Analysis
Global Mumps Vaccine Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Mumps Vaccine Industry growth. Mumps Vaccine market has been segmented with the help of its Age Type, Distribution channel , and others. Mumps Vaccine market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
As per Analysis, the Paediatric segment leading the Mumps Vaccine market.
Due to the increasing number of patients with infectious diseases like measles and mumps and the rise in research activities pertaining to paediatric vaccines, the paediatric segment held the largest proportion of the mumps vaccines market share and anticipated to continue to do so throughout the forecast period.
- Adult
- Paediatric
Mumps Vaccine Market Share (%) by Age Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Mumps Vaccine Industry. Request a Free Sample PDF!
By Distributional Channel, the Hospitals and clinics segment holds the major revenue share of Mumps Vaccine Market!
The hospital and clinics dominate the market. The hospital and medical centre segment should maintain its economic performance over the forecast period. Having qualified medical staff in hospitals and paediatric centres helps to better serve patients; This is a major driver for global business expansion and a major driver for the growth of hospitals and medical centres.
- Hospital & Clinic
- Vaccination Centres
Mumps Vaccine Market Share (%) by Distribution channel in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Bio :
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Mumps Vaccine Market is witnessing significant growth in the near future.
In 2023, the Adult segment accounted for noticeable share of global Mumps Vaccine Market and is projected to experience significant growth in the near future.
The Hospital & Clinic segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Sanofi SA , AstraZeneca and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions (FAQs)
The mumps vaccines are also called MMR vaccines, which protect against measles, mumps, and rubella. Children typically receive the first dose between the ages of 9 and 15 months, followed by the second dose between the ages of 15 and 6 years, with a Minimum of four weeks in between each dose.
The Mumps vaccine market is valued at USD 48.8 billion in 2022 and will be USD 35.8 billion by 2030 with a CAGR of 1.9% during the forecast period.
The players included Sanofi SA, Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Novartis, CSL limited, VBI Vaccines, Bharat Biotech.
Increasing research for combination vaccines and increasing infection are prime drivers of the market.
Yes, the report includes a COVID-19 impact analysis.
North America is anticipated to be the leading region in this market
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Mumps Vaccine Market
Latest Articles about Mumps Vaccine Market
This increase in incidence has raised concerns about the spread of mumps and the need for effective preventive measures. The highly contagious nature of the disease necessitates vaccination to prevent outbreaks and protect the pediatric population.
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_expenditure_statistics
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Mumps Vaccine Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Age Type | Adult, Paediatric |
| Distribution channel | Hospital & Clinic, Vaccination Centres |
| List of Competitors | Sanofi SA, Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Novartis, CSL limited, VBI Vaccines, Bharat Biotech |
Expand All
This chapter will help you gain GLOBAL Market Analysis of Mumps Vaccine. Further deep in this chapter, you will be able to review Global Mumps Vaccine Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Mumps Vaccine Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Mumps Vaccine Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Mumps Vaccine Revenue Market Size By Region
-
-
1.3 Global Mumps Vaccine Market Size By Age Type 2019 -2031
-
1.3.1 Adult Market Size
-
1.3.2 Paediatric Market Size
-
-
1.4 Global Mumps Vaccine Market Size By Distribution channel 2019 -2031
-
1.4.1 Hospital & Clinic Market Size
-
1.4.2 Vaccination Centres Market Size
-
-
1.5 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.6 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.6.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.6.2 Global Market Revenue Split By Age Type
-
1.6.3 Global Market Revenue Split By Distribution channel
-
1.6.4 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Mumps Vaccine Market Size 2019 - 2031
-
2.1.1 North America Mumps Vaccine Market Size By Country 2019 - 2031
-
2.1.2 North America Mumps Vaccine Market Size by Age Type 2019 -2031
-
2.1.2.1 North America Adult Market Size
-
2.1.2.2 North America Paediatric Market Size
-
-
2.1.3 North America Mumps Vaccine Market Size by Distribution channel 2019 -2031
-
2.1.3.1 North America Hospital & Clinic Market Size
-
2.1.3.2 North America Vaccination Centres Market Size
-
-
-
2.2 Add-Ons: Customize the Report Edition
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
-
2.2.1 North America Company Market Share 2019 till 2023
-
2.2.2 Qualitative Analysis for North America Market
Qualitative Analysis for the North America Market: North America Mumps Vaccine Market Trends North America Mumps Vaccine Technological Road Map North America Mumps Vaccine Market Drivers North America Mumps Vaccine Market Restraints North America Mumps Vaccine Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
-
-
2.3 Executive Summary North America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
-
2.3.1 North America Market Summary 2019 vs 2024 vs 2031
-
2.3.2 North America Market Revenue Split By Age Type
-
2.3.3 North America Market Revenue Split By Distribution channel
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Mumps Vaccine Market Size 2019 - 2031
-
3.1.1 Europe Mumps Vaccine Market Size By Country 2019 - 2031
-
3.1.2 Europe Mumps Vaccine Market Size by Age Type 2019 -2031
-
3.1.2.1 Europe Adult Market Size
-
3.1.2.2 Europe Paediatric Market Size
-
-
3.1.3 Europe Mumps Vaccine Market Size by Distribution channel 2019 -2031
-
3.1.3.1 Europe Hospital & Clinic Market Size
-
3.1.3.2 Europe Vaccination Centres Market Size
-
-
-
3.2 Add-Ons: Customize the Report Edition
-
3.2.1 Europe Company Market Share 2019 till 2023
-
3.2.2 Qualitative Analysis for Europe Market
-
-
3.3 Executive Summary Europe Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
-
3.3.1 Europe Revenue Market Summary 2019 vs 2024 vs 2031
-
3.3.2 Europe Market Revenue Split By Age Type
-
3.3.3 Europe Market Revenue Split By Distribution channel
-
Chapter 4 Asia-Pacific Market Analysis
-
4.1 Asia Pacific Mumps Vaccine Market Size 2019 - 2031
-
4.1.1 Asia Pacific Mumps Vaccine Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Mumps Vaccine Market Size by Age Type 2019 -2031
-
4.1.2.1 Asia Pacific Adult Market Size
-
4.1.2.2 Asia Pacific Paediatric Market Size
-
-
4.1.3 Asia Pacific Mumps Vaccine Market Size by Distribution channel 2019 -2031
-
4.1.3.1 Asia Pacific Hospital & Clinic Market Size
-
4.1.3.2 Asia Pacific Vaccination Centres Market Size
-
-
-
4.2 Add-Ons: Customize the Report Edition
-
4.2.1 Asia Pacific Company Market Share 2019 till 2023
-
4.2.2 Qualitative Analysis for Asia Pacific Market
-
-
4.3 Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
-
4.3.1 Asia Pacific Market Summary 2019 vs 2024 vs 2031
-
4.3.2 Asia Pacific Market Revenue Split By Age Type
-
4.3.3 Asia Pacific Market Revenue Split By Distribution channel
-
Chapter 5 South America Market Analysis
-
5.1 South America Mumps Vaccine Market Size 2019 - 2031
-
5.1.1 South America Mumps Vaccine Revenue Market Size By Country 2019 - 2031
-
5.1.2 South America Mumps Vaccine Market Size by Age Type 2019 -2031
-
5.1.2.1 South America Adult Market Size
-
5.1.2.2 South America Paediatric Market Size
-
-
5.1.3 South America Mumps Vaccine Market Size by Distribution channel 2019 -2031
-
5.1.3.1 South America Hospital & Clinic Market Size
-
5.1.3.2 South America Vaccination Centres Market Size
-
-
-
5.2 Add-Ons: Customize the Report Edition
-
5.2.1 South America Company Market Share 2019 till 2023
-
5.2.2 Qualitative Analysis for South America Market
-
-
5.3 Executive Summary South America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
-
5.3.1 South America Market Summary 2019 vs 2024 vs 2031
-
5.3.2 South America Market Revenue Split By Age Type
-
5.3.3 South America Market Revenue Split By Distribution channel
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Mumps Vaccine Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Mumps Vaccine Revenue Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Mumps Vaccine Market Size by Age Type 2019 -2031
-
6.1.2.1 Middle East and Africa Adult Market Size
-
6.1.2.2 Middle East and Africa Paediatric Market Size
-
-
6.1.3 Middle East and Africa Mumps Vaccine Market Size by Distribution channel 2019 -2031
-
6.1.3.1 Middle East and Africa Hospital & Clinic Market Size
-
6.1.3.2 Middle East and Africa Vaccination Centres Market Size
-
-
-
6.2 Add-Ons: Customize the Report Edition
-
6.2.1 Middle East and Africa Company Market Share 2019 till 2023
-
6.2.2 Qualitative Analysis for Middle East and Africa Market
-
-
6.3 Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
-
6.3.1 Middle East and Africa Market Summary 2019 vs 2024 vs 2031
-
6.3.2 Middle East and Africa Market Revenue Split By Age Type
-
6.3.3 Middle East and Africa Market Revenue Split By Distribution channel
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Mumps Vaccine Market Size by Age Type 2019 -2031
-
7.1.2 Country 1Mumps Vaccine Market Size by Distribution channel 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Mumps Vaccine Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Sanofi SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Pfizer
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 AstraZeneca
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Johnson & Johnson
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 GlaxoSmithKline
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Novartis
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 CSL limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 VBI Vaccines
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Bharat Biotech
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Age Type Analysis 2019 -2031, will provide market size split by Age Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Age Type Analysis 2019 -2031
-
10.1 Adult
-
10.1.1 Global Mumps Vaccine Revenue Market Size and Share by Adult 2019 -2031
-
-
10.2 Paediatric
-
10.2.1 Global Mumps Vaccine Revenue Market Size and Share by Paediatric 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Distribution channel Analysis 2019 -2031
-
11.1 Hospital & Clinic
-
11.1.1 Global Mumps Vaccine Revenue Market Size and Share by Hospital & Clinic 2019 - 2031
-
-
11.2 Vaccination Centres
-
11.2.1 Global Mumps Vaccine Revenue Market Size and Share by Vaccination Centres 2019 - 2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Mumps Vaccine market
Chapter 12 Research Findings
-
12.1 Key Takeaways
-
12.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
12.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Mumps Vaccine Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Mumps Vaccine Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Mumps Vaccine Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Mumps Vaccine Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Mumps Vaccine Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Mumps Vaccine Market
Key Questions Answered By Mumps Vaccine Market Report 2024
| Why Adult have a significant impact on Mumps Vaccine market? |
| What are the key factors affecting the Adult and Paediatric of Mumps Vaccine Market? |
| What is the CAGR/Growth Rate of Hospital & Clinic during the forecast period? |
| By type, which segment accounted for largest share of the global Mumps Vaccine Market? |
| Which region is expected to dominate the global Mumps Vaccine Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
